Biotech company, Curis, Inc., is making strides in the discovery and development of drug candidates for the treatment of human cancers in the United States. The company's clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, currently undergoing Phase 1/2 clinical trials for the treatment of non-hodgkin lymphomas, acute myeloid leukemia, and myelodysplastic syndromes. Additionally, the company's pipeline includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and CA-170, an oral small molecule drug candidate designed to treat patients with solid tumors and lymphomas. Curis, Inc. also holds an established collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway antagonist for the treatment of advanced basal cell carcinoma. Furthermore, the company has joined forces with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds specifically tailored to the areas of immuno-oncology and precision oncology. Since its incorporation in 2000, Curis, Inc. has headquartered itself in Lexington, Massachusetts, and continues to be a pioneering force in the biotech industry.